Toripalimab Combined With Anlotinib for Patients With Advanced Relapsed or Refractory Gastric or Esophagogastric Junction Cancer (EGJC)

  • participants needed
  • sponsor
    The Affiliated Hospital of Qingdao University
Updated on 29 January 2023


Patients were aged >18 years with histological confirmed GC/EGJC and were refractory to the first line of therapy. Additional eligibility requirements included: 1 measurable disease at baseline per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v 1.1); Eastern Cooperative Oncology Group Performance status of 0 or 1; or life expectancy of 3 months and adequate organ function. The main exclusion criteria were interstitial lung disease, pulmonary fibrosis, active or prior autoimmune disease or active hepatitis, or history of anlotinib or any other PD-L1/PD-1 antagonist treatment. Patients with abdominal fistula, diverticulitis, gastrointestinal ulcerative disease or perforation, or abdominal abscess within the prior 4 weeks were also excluded. This study was an open, exploratory single-arm, phase II trial. Enrolled patients received anlotinib (12mg, po. qd, d1-14) combined with toripalimab (240 mg, inv, over 30 min once every 2 weeks).

Condition Gastric or Gastro-oesophageal Junction Carcinoma, GC/EGJC, second-line therapy, second line therapy, Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma, Refractory to the First Line of Therapy
Treatment ARID1A, ARID1A, FGFR2, FGFR2
Clinical Study IdentifierNCT04713059
SponsorThe Affiliated Hospital of Qingdao University
Last Modified on29 January 2023

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note